SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-373610
Filing Date
2017-12-19
Accepted
2017-12-19 16:08:55
Documents
5
Period of Report
2017-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d466346d8k.htm 8-K 18129
2 EX-4.1 d466346dex41.htm EX-4.1 41598
3 EX-10.1 d466346dex101.htm EX-10.1 98337
4 EX-99.1 d466346dex991.htm EX-99.1 18424
5 GRAPHIC g466346g1219061736190.jpg GRAPHIC 5306
  Complete submission text file 0001193125-17-373610.txt   185417
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 171264115
SIC: 2834 Pharmaceutical Preparations